Drug Profile
VAL BRO 03
Latest Information Update: 04 Oct 2019
Price :
$50
*
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bausch Health Companies
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriatic arthritis
Most Recent Events
- 04 Oct 2019 Discontinued - Phase-III for Psoriatic arthritis in USA (unspecified route)
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 13 Jan 2016 Phase-III clinical trials in Psoriatic arthritis in USA (unspecified route)